世界の急性骨髄性白血病（AML）治療市場は、2023年から2028年の予測期間に10.0％のCAGRで成長し2023年の38億ドルから2028年までに61億ドルに達すると予想されます。
目次
Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Chapter- 2: Summary and Highlights
Market Outlook
This Report Highlights
Chapter- 3: Market Overview and Definitions
Overview
Chapter- 4: Market Dynamics
Market Drivers
Market Opportunity
Market Restraints
Chapter- 5: Impact of COVID-19
Introduction
Chapter- 6: Market Breakdown by Region
Market Overview and Discussion
Rest of the World
Chapter- 7: Market Breakdown by Treatment Type
Market Overview and Discussion
Chapter- 8: Market Breakdown by Route of Administration
Market Overview and Discussion
Chapter- 9: Market Breakdown by Product
FLT3 Inhibitors
Table 21 : Global Market for AML Treatments, by Product, Through 2028
Figure 8 : Global Market Shares of AML Treatments, by Product, Through 2028
Chapter- 10: ESG Development
Introduction
Chapter- 11: Emerging Trends and Technologies
Introduction
Chapter- 12: Competitive Landscape
Overview
Industry Scenario
Company Shares
Chapter- 13: Patent Analysis
Patent Analysis by Manufacturer
Chapter- 14: Pipeline Analysis
Clinical Trail Scenario
Chapter- 15: M&A and Venture Funding Outlook
Introduction
Chapter- 16: Company Profiles
ABBVIE
AMGEN INC.
ASTELLAS PHARMA INC.
BAYER AG
BIOGEN
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter- 17: Appendix: Acronyms
Table 98 : Acronyms Used in This Report
